Has received: October 15, 2020
Accepted: January 20, 2022
We thank F. Zhang, I. Korsunsky, and S. Raychaudhuri for advice on bioinformatics analysis; M. Gurish and G. Keras for their assistance in patient recruitment and specimen processing; W. Apruzzese for helpful discussions; J. Toska for his help with Western transfers; and patients for their participation. Screening was performed at the BWH Human Immunology Center. We thank the members of the AMP RA/SLE Phase 1 network for their contributions.
Funding: This work was supported by NIH NIAID P01AI148102, NIH NIAMS P30 AR070253, and the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc.; Arthritis Foundation; Bristol-Myers Squibb Company; Foundation for the NIH; GlaxoSmithKline; Janssen Research and Development, LLC; Lupus Foundation of America; Lupus Research Alliance; Merck Sharp & Dohme Corp. ; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Pfizer Inc.; Rheumatology Research Foundation; and Sanofi and Takeda Pharmaceuticals International Inc.) created to develop new ways to identify and validate targets promising biologics for diagnosis and drug development. Funding for AMP was provided by NIH grants (UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2-AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691 , UH69-44 , and UM2-AR067678). DPS was supported by NIH NHLBI T32 Institutional Training Grant HL007627 and NIH NIAMS K08 AR075850.
Author’s contributions: Conceptualization: DPS, DAR and MBB Methodology: DPS, HNN and EG-R. Formal analysis: DPS and YJ Survey: DPS, HNN and EG-R. Resources: DPS, EG-R., AHJ, AFC, JKL, GSD, PB, BEE, JSC, EMM, JAS, and DJT Data curation: DPS Writing—original draft: DPS Writing—revision and editing: DPS, HNN, EG -R., YJ, AHJ, AFC, JKL, GSD, PB, BEE, JSC, EMM, JAS, DJT, DAR, EYK and MBB Visualization: DPS Supervision: MBB Project administration: DAR and MBB Acquisition financing: DPS and MBB
Competing interests: The authors declare that they have no competing interests. Accelerating Medicines Partnership and AMP are registered service marks of the US Department of Health and Human Services.
Availability of data and materials: RNA-seq of sorted monocyte populations with high and low expression of SLAMF7 is available from NCBI GEO GSE185508. RNA-seq of monocyte-derived macrophages stimulated in vitro is available from NCBI GEO GSE185509. All other data necessary to evaluate the conclusions of the article are present in the article or the supplementary documents.
Individual members of the AMP RA/SLE Phase 1 Network are listed in alphabetical order: Jen Anolik, William Apruzzese, Joan M. Bathon, Ami Ben-Artzi, David L. Boyle, Brendan Boyce, S. Louis Bridges, Vivian Bykerk, Kevin Deane, Edward DiCarlo, Laura Donlin, Tom Eisenhaure, Andrew Filer, Gary S. Firestein, Lindsy Forbess, Susan Goodman, Ellen Gravallese, Peter K. Gregersen, Joel Guthridge, V. Michael Holers, Diane Horowitz, Laura Hughes, Judith James, James Lederer, Arthur Mandelin, Mandy McGeachy, Larry Moreland, Nir Hacohen, Harris Perlman, Costantino Pitzalis, Soumya Raychaudhuri, Christopher Ritchlin, Bill Robinson, Jennifer Seifert, PJ Utz, Kevin Wei, Fan Zhang.